IGF1 and neoplasm: PPAR agonists (e.g., fenofibrate, troglitazone) reduce tumor progression in MB, NB, and OS by modulating IGF-I, lipid metabolism, and pro-apoptotic pathways. TRIM46 regulates PPAR signaling, influencing tumor outcomes.